The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech ...

In a news release, SRPT said the patient succumbed to acute liver failure after receiving the Sarepta Elevidys therapy, the only FDA-approved gene therapy for Duchenne muscular dystrophy.

Mandimycin is structurally similar to the last-line-of-defense antifungal amphotericin B, another glycosylated polyene macrolide. But instead of binding to ergosterol in the fungal cell membrane as ...

Elevidys, Sarepta’s gene therapy for DMD, has demonstrated significant commercial success since receiving expanded label approval for patients aged 6 and older. The therapy has exceeded revenue ...

Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...

A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the treatment The company plans to update prescribing information after ...

Elevidys, Sarepta’s gene therapy for DMD, has demonstrated significant commercial success since receiving expanded label approval for patients aged 6 and older. The therapy has exceeded revenue ...

Sarepta fell heavily by 27.44 percent on Tuesday to finish at $73.54 apiece as investors disposed of shares in the company following twin news of death associated with its treatment Elevidys.

The patient in this case had suffered acute liver failure following the Elevidys infusion. Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy (DMD) who received ...

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment. The company behind the drug, Sarepta ...